DGDilan Gezer

Dilan Gezer

*This is an algorithmically generated author record based on publicly available information.

Dilan Gezer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel 1H-Pyrrole-2,5-Dione derivatives as potential Anti-Diabetic Agents: Design, Synthesis, in vitro, in Ovo, and Molecular Docking Studies

    by Dilan Gezer, Zeynep Ozyildiz, Zeliha Gokmen, Eda Dagsuyu, Ozlem Sacan, Remzi Okan Akar, Elifnur Gizem Yildirim, Engin Ulukaya, Kaan Adacan, Aslı KUTLU

    Diabetes mellitus (DM) is the most common metabolism-related health problem across the world and new therapeutics are still emerging into the market. One of the treatments is the inhibition of α-glucosidase, which is a validated therapeutic strategy for mitigating postprandial hyperglycemia in Type 2 DM. However, the clinical utility of current inhibitors, such as Acarbose, is often limited by gastrointestinal side effects and suboptimal pharmacokinetics linked to their surface-binding modes. In this study, we reported the design, synthesis, and biological evaluation of a novel series of 1H-Pyrrole-2,5-dione derivatives, targeting the deep catalytic cleft of human acid α-glucosidase (rhGAA). In vitro studies revealed that all the new compounds showed higher enzyme inhibitory activity than Acarbose (IC50 = 54.14 ± 6.43 mM). In in ovo model, compound 3d worked best to reduce blood glucose levels (around 48 mg/mL) and maintained this effect within 3 hours. Molecular docking calculations covering the whole protein surface confirmed the catalytic pocket as the primary binding site, followed by focused docking, which identified 3g as the top in silico hit (-9.35 kcal/mol). In vitro kinetic experiments revealed that 5c possessed the highest inhibitory potential (IC50 = 0.21 mM) and performed significantly better than Acarbose, while structural dynamics analysis of 5c highlighted its conformational instability. Consequently, compound 3d (IC50 = 0.64 mM) was selected as the lead candidate to effectively inhibit rhGAA. Structural fingerprinting elucidated a unique "Anchor Mechanism" for 3d, characterized by a critical hydrogen bond with ARG281.